Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Plasma exchange and immunoadsorption
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

Plasma exchange and immunoadsorption

2 evidence topics · 2 sources

Existing desensitization approaches

“Desensitisation is currently based on protocols using apheresis and/or medicinal products used off-label.” (opens the source at this quote in a new tab)

Guideline-supported antibody removal with adjunctive therapy

“plasma exchange or immunoadsorption, supplemented with IViG and/or anti-CD20 antibody.” (opens the source at this quote in a new tab)